|
KMID : 0624620210540010021
|
|
BMB Reports
2021 Volume.54 No. 1 p.21 ~ p.30
|
|
|
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
|
|
Kim Ji-Hae
Lee Kun-Joo
Lee Seung-Woo
|
|
|
Abstract
|
|
|
|
Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients’ prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells or targets for CPIs is a limitation for patients with poor prognosis. Since interleukin (IL)-2 and IL-7 are cytokines that target many aspects of T-cell responses, they have been used to treat cancers. In this review, we focus on the basic biology of how these cytokines regulate T-cell response and on the clinical trials using the cytokines against cancer. Further, we introduce several recent studies that aim to improve cytokines’ biological activities and find the strategy for combination with other therapeutics.
|
|
|
KEYWORD
|
|
|
Cancer immunotherapy, Cytokine, IL-2, IL-7, T cells
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|